Prevalence of Aspergillus-Derived Mycotoxins (Ochratoxin, Aflatoxin, and Gliotoxin) and Their Distribution in the Urinalysis of ME/CFS Patients. — CFSMEATLAS
Prevalence of Aspergillus-Derived Mycotoxins (Ochratoxin, Aflatoxin, and Gliotoxin) and Their Distribution in the Urinalysis of ME/CFS Patients.
Wu, Ting Yu, Khorramshahi, Taura, Taylor, Lindsey A et al. · International journal of environmental research and public health · 2022 · DOI
Quick Summary
This study looked for mold-related toxins in the urine of 236 ME/CFS patients who had been exposed to mold in water-damaged buildings. Researchers found evidence of these toxins in 92.4% of the patients tested, with a toxin called ochratoxin A being the most common. The study provides preliminary evidence that mold exposure may be connected to ME/CFS in this patient group, though more research is needed to understand if mold actually causes the illness.
Why It Matters
This study explores a potential environmental trigger (mycotoxin exposure) that may contribute to ME/CFS development, addressing a significant gap since ME/CFS pathophysiology remains unknown. For patients, understanding possible environmental risk factors could inform prevention strategies and inform clinical discussions about exposure history. For researchers, these preliminary findings suggest that controlled studies comparing mycotoxin levels in ME/CFS patients versus controls are warranted.
Observed Findings
92.4% of ME/CFS patients with chronic mold exposure history demonstrated detectable Aspergillus-derived mycotoxins in urinalysis
Ochratoxin A (OTA) was the most prevalent mycotoxin detected among the three toxins studied
Mycotoxin distributions (OTA, AF, GT) in urinalysis showed right-skewed patterns, indicating variable toxin levels across the patient population
Patient age distribution (30-50 years, predominantly female) was normally distributed
Study population was geographically limited to South Florida ME/CFS patients
Inferred Conclusions
Chronic mold exposure may be epidemiologically associated with ME/CFS in a subset of patients, particularly those from water-damaged building environments
Future controlled studies should directly compare mycotoxin levels between ME/CFS patients and appropriate control populations to establish causality
Ochratoxin A warrants particular attention in future investigations of mycotoxin and ME/CFS associations
Remaining Questions
Do unexposed ME/CFS patients or healthy controls exposed to mold show similar mycotoxin levels, and if not, is this association specific to ME/CFS?
Does the presence and level of mycotoxins correlate with ME/CFS symptom severity or disease progression?
What This Study Does Not Prove
This study does not prove that mold exposure causes ME/CFS—it only shows an association in patients who already have the illness and reported mold exposure. Without a control group of unexposed people or people with mold exposure but without ME/CFS, the study cannot determine if mycotoxin presence is unique to ME/CFS or causally related to disease onset. The findings are specific to South Florida and may not apply to ME/CFS patients in other geographic regions.